The objective is to demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of the change from baseline (D1) in total ocular surface staining score assessed on Oxford 0-15 scale, in the study eye at the D36 visit.

The investigation is defined as a post-market stage. The clinical investigation design is confirmatory.

Main Inclusion Criteria (At Screening visit):

• Informed consent signed and dated (obtained prior to initiating any procedures).
• Patient aged ≥18 years old.
• Persistence of dry eye syndrome, despite artificial tears use in the previous month prior to the screening visit

Main Exclusion Criteria (At both Screening and Randomisation visits):

• Far Best-Corrected Visual Acuity (BCVA) ≥+0.7 LogMar (e.g., ≤0.2 in decimal value or ≤20/100 Snellen equivalent or ≤50 letters Early Treatment Diabetic Retinopathy Study (ETDRS)).
• Patient with previous or current ophthalmic condition

ITT

7 weeks from D-10 to D36 (+3 days)

AE: Any untoward medical occurrence, unintended disease or injury or untoward clinical signs in subjects, users or other persons whether or not related to IMD.

This includes events related to IMD or comparator, events related to the procedures involved, For users or other persons, this definition is restricted to events related to use of the IMD or comparator.

Adverse event is an incident. REPORTING: Any incident must report to Sponsor within 24 hours of awareness using incident form.